Winslow Evans & Crocker Inc. Sells 424 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Winslow Evans & Crocker Inc. lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,190 shares of the biopharmaceutical company’s stock after selling 424 shares during the quarter. Winslow Evans & Crocker Inc.’s holdings in Gilead Sciences were worth $1,096,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in shares of Gilead Sciences by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 16,867,065 shares of the biopharmaceutical company’s stock worth $1,053,332,000 after purchasing an additional 835,915 shares in the last quarter. Parnassus Investments CA boosted its position in shares of Gilead Sciences by 21.2% during the 1st quarter. Parnassus Investments CA now owns 13,074,555 shares of the biopharmaceutical company’s stock worth $849,976,000 after purchasing an additional 2,288,767 shares in the last quarter. Norges Bank bought a new position in shares of Gilead Sciences during the 4th quarter worth about $798,882,000. Sanders Capital LLC boosted its position in shares of Gilead Sciences by 5.0% during the 1st quarter. Sanders Capital LLC now owns 11,291,933 shares of the biopharmaceutical company’s stock worth $793,701,000 after purchasing an additional 539,793 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Gilead Sciences by 3.3% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,213,760 shares of the biopharmaceutical company’s stock worth $338,947,000 after purchasing an additional 167,292 shares in the last quarter. 78.85% of the stock is currently owned by institutional investors.
GILD has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Hersha Hospitality Trust from a “buy” rating to a “hold” rating in a report on Thursday, May 2nd. Cowen set a $150.00 target price on shares of Tesla and gave the stock a “sell” rating in a report on Friday, May 3rd. BMO Capital Markets set a $76.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Monday, July 15th. Goldman Sachs Group set a $27.00 target price on shares of Melco Resorts & Entertainment and gave the stock a “buy” rating in a report on Tuesday, May 28th. Finally, Evercore ISI restated a “buy” rating on shares of Gilead Sciences in a report on Friday, May 17th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $81.56.
Shares of GILD stock traded down $0.52 during trading hours on Tuesday, hitting $67.35. 3,472,588 shares of the company were exchanged, compared to its average volume of 5,225,046. The company’s fifty day moving average price is $67.26. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.53. Gilead Sciences, Inc. has a 52-week low of $60.32 and a 52-week high of $79.61. The firm has a market cap of $85.83 billion, a PE ratio of 10.95, a price-to-earnings-growth ratio of 4.05 and a beta of 1.12.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.53 by $0.23. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The company had revenue of $5.28 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the business posted $1.48 EPS. Gilead Sciences’s quarterly revenue was up 3.8% compared to the same quarter last year. Research analysts forecast that Gilead Sciences, Inc. will post 6.62 EPS for the current fiscal year.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: Why is the price-sales ratio important?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.